Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate.

BACKGROUND Although tumor necrosis factor-α (TNF-α) levels are increased in patients with atrial fibrillation (AF), its role in the pathogenesis of AF is unclear. We investigated whether direct delivery of TNF-α could induce atrial fibrosis. METHODS AND RESULTS TNF-α (4 μg/kg) was injected into the tail vein of 20 male Swiss albino mice (TNF group) and saline into 20 control mice (CON group). The dose was carefully chosen to avoid any significant decrease in left ventricular (LV) function. Animals were killed after 16 weeks and their atria examined for fibrosis. We found increased atrial fibrosis in the TNF group compared with the CON group [372.8±21.5 arbitrary units (a.u.) vs. 56.9±6.5 a.u., respectively, mean±SEM; P<0.0001] and decreased connexin-40 immunofluorescence [7.5±0.4 a.u vs. 40.4±1.9 a.u, respectively; P<0.0001]. Transforming growth factor-β [TGF-β: 95.6±1.8 a.u vs. 29.4±5.8 a.u; P<0.001], α-smooth muscle actin (α-SMA: 97.9±13.0 a.u vs. 50.1±18.5 a.u; P<0.05] and matrix metalloproteinase 2 (MMP-2)/GAPDH levels [157.3±26.4 a.u vs. 105.8±13.3 a.u; P<0.05] were also increased in the TNF group. CONCLUSIONS TNF-α is involved in the pathogenesis of atrial fibrosis and altered connexin-40 expression in mice through the TGF-β signaling pathway, activation of myofibroblasts and increased secretion of MMPs. Collectively, these changes may contribute to the arrhythmogenic substrate and development of AF. 

[1]  M. Fishbein,et al.  Triggered firing and atrial fibrillation in transgenic mice with selective atrial fibrosis induced by overexpression of TGF-β1. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[2]  T. Koh,et al.  Nox2 and Nox4 mediate tumour necrosis factor-α-induced ventricular remodelling in mice , 2011, Journal of cellular and molecular medicine.

[3]  Shuilin Huang,et al.  Plasma levels of tumor necrosis factor-&agr; and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase , 2011, Critical care medicine.

[4]  H. Pak,et al.  High plasma concentrations of transforming growth factor-β and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[5]  G. Heusch,et al.  TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. , 2010, Pharmacology & therapeutics.

[6]  A. Leask Potential Therapeutic Targets for Cardiac Fibrosis: TGF&bgr;, Angiotensin, Endothelin, CCN2, and PDGF, Partners in Fibroblast Activation , 2010, Circulation research.

[7]  Qingxia Chen,et al.  Role of inflammation and oxidative stress in atrial fibrillation. , 2010, Heart rhythm.

[8]  S. Nattel,et al.  Changes in Connexin Expression and the Atrial Fibrillation Substrate in Congestive Heart Failure , 2009, Circulation research.

[9]  J. S. Janicki,et al.  TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. , 2009, American journal of physiology. Heart and circulatory physiology.

[10]  R. Hauer,et al.  The role of connexin40 in atrial fibrillation. , 2009, Cardiovascular research.

[11]  G. Tiegs,et al.  Down-regulation of the De-ubiquitinating Enzyme Ubiquitin-specific Protease 2 Contributes to Tumor Necrosis Factor-α-induced Hepatocyte Survival* , 2009, Journal of Biological Chemistry.

[12]  N. Severs,et al.  Gap junctions; , 2008 .

[13]  S. Nattel,et al.  Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[14]  Jessica Brooks,et al.  Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis , 2008 .

[15]  John A Kellum,et al.  Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. , 2007, Archives of internal medicine.

[16]  P. Vardas,et al.  Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. , 2007, International journal of cardiology.

[17]  C. Tai,et al.  Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. , 2007, Life sciences.

[18]  Thomas H Everett,et al.  Atrial fibrosis and the mechanisms of atrial fibrillation. , 2007, Heart rhythm.

[19]  V. Shusterman,et al.  Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. , 2005, American journal of physiology. Heart and circulatory physiology.

[20]  T. Roskams,et al.  Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. , 2005, Cardiovascular research.

[21]  J. Omens,et al.  Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. , 2005, Cardiovascular research.

[22]  P. Aukrust,et al.  Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. , 2005, The American journal of cardiology.

[23]  S. Ball,et al.  Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. , 2004, Cardiovascular research.

[24]  M. Berry,et al.  Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[26]  A. Phillips,et al.  TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. , 2003, Experimental cell research.

[27]  B. Bozkurt,et al.  Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. , 2002, Cardiovascular research.

[28]  C. Long,et al.  Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo , 2001, Pflügers Archiv.

[29]  B. Bozkurt,et al.  Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.

[30]  V. Petrov,et al.  Induction of cardiac fibrosis by transforming growth factor-beta(1). , 2000, Molecular genetics and metabolism.

[31]  A. Harken,et al.  Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. , 1999, Critical care medicine.

[32]  R. Peshock,et al.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.

[33]  D. Meldrum Tumor necrosis factor in the heart. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  J. Mege,et al.  Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. , 1997, Critical care medicine.

[35]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[36]  D. Mann,et al.  Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. , 1996, Circulation.

[37]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[38]  R. Kloner,et al.  Echocardiographic and cardiac Doppler assessment of mice. , 1995, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.